Investors were excited about the possibility of a buyout with a high price tag.France-based biotech Abivax (ABVX +20.69%) landed on many investors' buy lists on Monday, following a media report that a giant American peer was interested in acquiring it. With that considerable tailwind at its back, Abivax's share price zoomed nearly 21% higher across that day's trading session. On the hunt?According to a widely disseminated article in French periodical La Lettre, that interested party is none other than Ameri ...

智通财经APP获悉，周一，Abivax S.A.(ABVX.US)开盘大涨近15%，逼近此前历史新高，现报131.59美 元。消息面上，据报道，礼来公司已与法国当局展开初步讨论，以探索可能收购生物技术公司Abivax的 事宜。报道称，礼来在12月初与法国财政部进行了初步会谈，以评估收购Abivax是否会受到该国外资投 资审查规则的限制。根据报道，礼来还讨论了国有投资者Bpifrance作为少数股东可能参与的情况。 ...

周一，Abivax S.A.(ABVX.US)开盘大涨近15%，逼近此前历史新高，现报131.59美元。消息面上，据报 道，礼来公司已与法国当局展开初步讨论，以探索可能收购生物技术公司Abivax的事宜。报道称，礼来 在12月初与法国财政部进行了初步会谈，以评估收购Abivax是否会受到该国外资投资审查规则的限制。 根据报道，礼来还讨论了国有投资者Bpifrance作为少数股东可能参与的情况。 ...

Core Viewpoint - Abivax SA will be added to the Nasdaq Biotechnology Index effective December 22, 2025, marking a significant milestone for the company and enhancing its visibility in the global biotechnology community [2][3]. Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in patients with chronic inflammatory diseases [4]. - The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [4]. Nasdaq Biotechnology Index (NBI) Details - The NBI tracks the performance of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market, requiring companies to meet specific eligibility criteria such as minimum market capitalization and average daily trading volume [3]. - The index is evaluated annually in December and uses a modified capitalization-weighted methodology for its calculations [3].

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC)Novel Anti-Fibrotic P ...

Piper Sandler sets a price target of $142 for NASDAQ:ABVX, indicating a potential increase of 27.95%.The "Strong Buy" rating is driven by positive phase 3 ABTECT induction data for obefazimod, highlighting its potential in the ulcerative colitis therapy market.Abivax plans significant milestones in 2026, including filing for New Drug Application (NDA) and Marketing Authorization Application (MAA) if trials remain positive.Abivax SA (NASDAQ:ABVX) is a biopharmaceutical company focused on developing therapies ...

Core Insights - Abivax reported a significant increase in net loss for the nine months ending September 30, 2025, amounting to EUR 254.1 million, compared to EUR 136.9 million for the same period in 2024, reflecting a rise of EUR 117.3 million [3][5][10] Financial Performance - Total operating income decreased to EUR 4.1 million for the nine months ended September 30, 2025, down from EUR 8.1 million in 2024, a decline of EUR 4.0 million [3][5] - Total operating expenses rose to EUR 178.5 million, with research and development costs increasing by EUR 25.4 million to EUR 133.4 million, primarily due to costs associated with clinical programs for ulcerative colitis and Crohn's disease [3][5][6] - Operating loss increased by EUR 44.2 million to EUR 174.4 million for the nine months ending September 30, 2025, compared to EUR 130.2 million in 2024 [3][5] Cash Position - Cash and cash equivalents as of September 30, 2025, were EUR 589.7 million, a substantial increase from EUR 144.2 million as of December 31, 2024, primarily due to net proceeds from a public offering [5][8] - The company expects its cash runway to extend into Q4 2027 based on its current cash position [10] Shareholder Equity and Financial Position - Total assets increased to EUR 652.1 million as of September 30, 2025, compared to EUR 205.2 million at the end of 2024, reflecting a growth of EUR 446.8 million [5] - Total shareholders' equity rose to EUR 511.2 million from EUR 40.6 million, an increase of EUR 470.7 million [5] Operational Updates - Abivax has been actively presenting updates on its clinical trials, including late-breaking presentations at the 2025 United European Gastroenterology (UEG) Meeting, highlighting the progress of its lead drug candidate, obefazimod [4][10] - The company has made significant advancements in its clinical programs, particularly in ulcerative colitis and Crohn's disease, which are reflected in the increased R&D expenses [3][5][6]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - Abivax SA's stock is experiencing significant upward momentum due to speculation regarding a potential acquisition by Eli Lilly and Co, with the stock price having surged over 1,500% in the past six months [2][3]. Group 1: Stock Performance - Abivax stock is currently trading at $128.30, reflecting a 4.28% increase on the day of publication [6]. - The stock has shown explosive growth, driven by takeover speculation, particularly in light of Eli Lilly's recent activities in the pharmaceutical market [2][3]. Group 2: Clinical Developments - Abivax achieved a major milestone with its experimental treatment obefazimod, which demonstrated impressive efficacy in Phase 3 trials for patients with moderately to severely active ulcerative colitis [3]. - Additional clinical data presented at the United European Gastroenterology Meeting indicated that obefazimod 50mg led to clinically meaningful improvements across all subgroups in the pooled ABTECT 1 & 2 trials [4]. Group 3: Market Context - Eli Lilly's recent issuance of a 40-year bond has sparked speculation about potential acquisitions, with Abivax being a notable target alongside other companies like Viking Therapeutics [4]. - Eli Lilly's acquisition of Verve Group SE for approximately $1 billion, with potential total consideration reaching up to $1.3 billion, highlights the company's active pursuit of strategic acquisitions in the biotech space [5].

Core Insights - U.S. stocks exhibited mixed performance, with the Nasdaq Composite declining by over 100 points on Wednesday [1] - Daktronics, Inc. reported quarterly earnings of 35 cents per share, surpassing the analyst consensus estimate of 27 cents per share, and quarterly sales of $229.253 million, exceeding the consensus estimate of $214.077 million [1] Company Performance - Daktronics shares surged by 15.7% to $20.80 following the positive earnings report [2] - Photronics, Inc. saw its shares increase by 44% to $37.00 after reporting better-than-expected fourth-quarter results and issuing optimistic first-quarter guidance [3] - Nextdoor Holdings, Inc. gained 24.6% to $2.5050 after a positive social media mention regarding its valuation [3] - Braze, Inc. rose by 17.5% to $36.00 after raising its FY2026 adjusted EPS and sales guidance [3] - Dave & Buster's Entertainment, Inc. jumped 14% to $20.50 following its third-quarter results [3] - SuperX AI Technology Limited's shares increased by 13.8% to $19.63 [3] - GE Vernova Inc. rose by 11.8% to $699.59 after raising its FY28 outlook and dividend, along with expanding its buyback authorization [3] - DBV Technologies S.A. gained 11.2% to $19.09 [3] - Warby Parker Inc. rose by 11% to $25.77 [3] - Dyne Therapeutics, Inc. increased by 10.5% to $20.38 after announcing a $350 million public offering [3] - ABIVAX Société Anonyme rose by 8.6% to $133.24 [3] - Olema Pharmaceuticals, Inc. gained 8.1% to $28.67 [3] - The Middleby Corporation rose by 6.3% to $137.15 after an upgrade from Jefferies [3] - EchoStar Corporation increased by 5.6% to $98.80 following an upgrade from Morgan Stanley [3]